Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Establishment of a Prenatal Diagnosis Schedule As Part of a Prophylaxis Program of Factor Xiii Deficiency in the Southeast of Iran Publisher Pubmed



Naderi M1 ; Reykande SE2 ; Dorgalaleh A3, 4 ; Alizadeh S3 ; Tabibian S3 ; Einollahi N5 ; Moghaddam EM6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatrics Hematology and Oncology, Ali Ebn-e Abitaleb Hospital Research Center for Children and Adolescents Health, Zahedan University of Medical Sciences, Zahedan, Iran
  2. 2. Department of Hematology, Allied Medical School, Stud. Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Hematology and Blood Transfusion, School of Allied Medicine, Tehran University of Medical Sciences, Iran
  5. 5. Department of Biochemistry, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Genetic of Non-Communicable Disease Researcher Center, Zahedan University of Medical Sciences, Zahedan, Iran

Source: Blood Coagulation and Fibrinolysis Published:2016


Abstract

Factor XIII deficiency (FXIIID) is an extremely rare bleeding disorder with a prevalence of 1 in 3 million in the general population. Compared to its global incidence, it has the greatest prevalence in Sistan and Baluchistan Province in the southeast of Iran. The high incidence of FXIIID in this region causes a high rate of morbidity and mortality among the affected individuals because of life-threatening episodes such as central nervous system (CNS) bleeding, umbilical cord bleeding, as well as miscarriage. CNS bleeding leads to a considerable number of neurological and behavioral complications. Therefore, we have designed an established prenatal diagnosis (PND) program to prevent the increasing incidence of life-threatening bleeding episodes and related complications among neonates with congenital FXIIID. This study was conducted from September 2013 to August 2014. A consent form was signed by the parents. Fetal sampling was done via abdominal chorionic villus sampling passage under local anesthesia and ultrasonic guidance within the first trimester of pregnancy. Fetal DNA was extracted, and PCR-restriction fragment length polymorphism was performed for the only reported mutation of FXIII (Trp187Arg) in the southeast of Iran. During the period of study, PND was performed on eight fetuses. Six fetuses were offspring of parental consanguineous marriages, and all of them had a positive family history of FXIIID. Seven out of the eight fetuses had a family member with CNS bleeding due to FXIIID. Four fetuses had a FXIIID-related death. One of the fetuses bore homozygous Trp187Arg mutation, whereas six were heterozygous, and one of the mothers gave birth to an unaffected fetus. To the best of our knowledge, PND is a possible solution to control high incidence of lifethreatening episodes of FXIIID in southeast Iran. © 2016 Wolters Kluwer Health, Inc. All rights reserved.